Xinfeng capsule improves hyperinflammation-associated hypercoagulability and self-perception in osteoarthritis by regulating KLF4 through METTL14-mediated m

Background: Our previous studies have demonstrated that Xinfeng Capsule (XFC) exerts therapeutic effects on hyperinflammation-associated hypercoagulability and self-perception of patients (SPP) with osteoarthritis (OA). However, the underlying molecular mechanisms remain unclear. Objective: This study aimed to explore the mechanism by which XFC improves hyperinflammation-associated hypercoagulability and SPP in OA. Methods: A keyword co-occurrence network was constructed to identify key targets involved in hyperinflammation-associated hypercoagulability in OA patients. m6A prediction databases and RNA pull-down assays were used to identify potential m6A modification sites and key binding proteins of lncRNA MEG3. Peripheral blood mononuclear cells (PBMCs) were collected from OA patients and healthy controls, and global m Results: The keyword co-occurrence network analysis indicated that inflammatory factors [interleukin-6 (IL-6), IL-10, and tumor necrosis factor-α (TNF-α)] and coagulation-related factors [tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1), and prostaglandin I Conclusion: This study indicates that XFC may upregulate the expression of lncRNA MEG3 and KLF4 by modulating METTL14-mediated m6A modification of lncRNA MEG3. Through this mechanism, XFC may regulate inflammatory responses and coagulation disorders, thereby improving SPP and exerting therapeutic effects on hyperinflammation-associated hypercoagulability in patients with OA.